Product overview highlighting TYRX III technology, infection reduction benefits, pocket health outcomes, and enhanced usability features.
Absorbable antibacterial envelopes
TYRX™ III absorbable antibacterial envelope
<p>TYRX™ technology is an absorbable antibacterial envelope used with cardiac implantable electronic devices.</p>
Product details
The TYRX™ III envelope surface has been redesigned to be 47% smoother.3
The TYRX™ III envelope features an ~30% wider opening.3
The envelope seam has been reduced by ~40%.3
Enhanced
Improved usability
- 47% smoother mesh reduces friction3
- Wider envelope opening and narrower seam simplify device insertion3
Effective
Unmatched clinical evidence
- Over 2 million patients protected by TYRX™ technology4
- Same effectiveness, absorption, and antibiotic elution as existing TYRX™ envelope†,5
- TYRX™ technology demonstrated 61% reduction of pocket infections in WRAP-IT randomized controlled trial1
Endorsed
Endorsed by physician societies worldwide
- TYRX™ technology recommended by international consensus and recognized by AHA scientific statement6-9
- Backed by Medtronic Outcomes Protection Program
Enhanced
Improved usability
- 47% smoother mesh reduces friction3
- Wider envelope opening and narrower seam simplify device insertion3
Effective
Clinical evidence
- Over 2 million patients protected by TYRX™ technology4
- Same effectiveness, absorption, and antibiotic elution as existing TYRX™ envelope†,5
- TYRX™ technology demonstrated 61% reduction of pocket infections in WRAP-IT randomized controlled trial1
Endorsed
Endorsed by physician societies worldwide
- TYRX™ technology recommended by international consensus and recognized by AHA scientific statement6–9
- Backed by Medtronic Outcomes Protection Program
Ordering information
| Item number | Quantity | Size |
Dimensions |
|---|---|---|---|
| CMEZ6122 | Single unit | Medium | 2.5” (6.3 cm) x 2.7” (6.9 cm) |
| CMEZ6133 | Single unit | Large | 2.9” (7.3 cm) x 3.5” (8.8 cm) |
Resources
Similar products
† TYRX™ III Envelope equivalence demonstrated in preclinical testing.
- Tarakji KG, Mittal S, Kennergren C, et al. Antibacterial envelope to prevent cardiac implantable device infection. N Engl J Med. 2019; 380(20):1895–1905. doi:10.1056/NEJMoa1901111.
- Philippon F, Ladich E, Virmani R, et al. An absorbable antibacterial envelope promotes development of a healthy device pocket: Results of the TYRX Pocket Health Study. J Cardiovasc Electrophysiol. 2025;36(8):1978–1986. doi:10.1111/jce.16766.
- TYRX™ III absorbable antibacterial envelope form factor comparison. May 2026. Medtronic data on file.
- TYRX™ Technology 2 million patients milestone. June 2026. Medtronic data on file.
- TYRX™ III absorbable antibacterial envelope drug elution profile. May 2026. Medtronic data on file.
- Keene D, Nielsen JC, Burri H, et al. Cardiac implantable electronic device upgrades and downgrades: a clinical consensus statement of the European Heart Rhythm Association (EHRA) of the ESC, the Asia Pacific Heart Rhythm Association (APHRS), Canadian Heart Rhythm Society (CHRS), Heart Rhythm Society (HRS), and the Latin American Heart Rhythm Society (LAHRS). Europace. 2025;27(12):euaf252. doi:10.1093/europace/euaf252.
- Baddour LM, Garrigos ZE, Sohail MR, et al. Update on cardiovascular implantable electronic device infections and their prevention, diagnosis, and management: A scientific statement from the American Heart Association: Endorsed by the International Society for Cardiovascular Infectious Diseases. Circulation. 2024;149(2):e201–e216. doi:10.1161/CIR.0000000000001187.
- Blomström-Lundqvist C, Traykov V, Erba PA, et al. ESC Scientific
- Cha Y-M, El-Chami MF, Liu CF, et al. 2026 HRS/AHA/APHRS/EHRA/IDSA/LAHRS/PACES/STS expert consensus statement update on cardiovascular implantable electronic device lead management and extraction. Heart Rhythm. 2026;23(8):e1716-e1792. doi:10.1016/j.hrthm.2026.04.015.
This product is licenced with Health Canada as TYRX III ABSORBABLE ANTIBACTERIAL ENVELOPE on Health Canada licence number 109121.